Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

PRecision Integrated Saturation Monitor (PRISM)

30 giugno 2026 aggiornato da: Danielle Gottlieb Sen, Le Bonheur Children's Hospital

PRISM: PRecision Integrated Saturation Monitor A Novel Approach to Monitoring Oxygen Saturation in Children A Prospective, Observational, Comparative Validation Clinical Study to Evaluate the Accuracy of a Novel Abdominal Pulse Oximeter With Integrated Motion Detection and Skin Tone Calibration Against Arterial Blood Gas (SaO₂) Measurements and Conventional Fingertip Pulse Oximetry (SpO₂) in Pediatric Patients.

The purpose of this study is to find out if an abdominal pulse oximeter device is as accurate as a conventional fingertip pulse oximeter in pediatric patients. In this study, we will be collecting data from your medical record while you are being treated in the hospital for your clinical care. Your baby will be in the study for 3 days. There will be no additional study visits. We will collect information already being obtained while your baby is at the hospital.

Panoramica dello studio

Descrizione dettagliata

Conventional pulse oximeters are prone to motion artifacts due to their placement on high-activity limbs. Traditionally, inpatient pulse oximetry relies on clinical staff to verify the accuracy of readings and distinguish between real and false desaturation events. However, in outpatient environments, caregivers are left to manage and interpret signals that may not provide reliable information about their child's health. PRISM aims to improve pulse oximetry monitoring for children. We will test an innovative pulse oximeter prototype that mitigates motion artifacts by shifting the monitoring location from a high-activity limb to the abdomen while incorporating motion detection capabilities. Previously, we have successfully developed an abdomen-worn prototype for collection of ECG signals for infant monitoring (Figure 1). We obtained high-quality signals with a robust correlation to the gold-standard ECG. Our preliminary results demonstrate the feasibility of collecting physiological signals from the abdomen, supporting its use as a novel, baby-friendly monitoring site. Figure 1. Comparison of ECG signals between gold-standard chest ECG and abdomen ECG. Protocol Version 2: 11 June 2026 IRB NUMBER: STUDY00000178 IRB APPROVAL DATE: 6/29/2026 IRB EXPIRATION DATE: 6/2/2027 We will incorporate a commercially available pulse oximetry sensor into a biocompatible, flexible, 3D printed housing. The child-focused design will be specific for application to the abdomen and will clip onto the diaper or pants of the baby; the tension from the diaper or pants will provide ample force to ensure sufficient contact between the device and the skin to achieve robust signals (Figure 2). The device will be removed with each diaper change. Figure 2. Schematic demonstrating the proposed pulse oximeter and its abdominal application As pulse oximetry uses optical sensors, external factors such as ambient light may interfere with data acquisition. Additionally, maintaining reliable contact with the skin is crucial to ensure the emitted light penetrates the underlying tissue, rather than reflecting off the skin's surface. Here, we will design the sensor housing to shield the pulse oximetry sensors from ambient light and provide a contact surface flexible enough for direct skin-to-sensor contact. The PRISM prototype is intended to minimize the impact of motion artifacts, a common phenomenon that leads to inaccurate readings and unnecessary alarms. By shifting the monitoring location from high-activity limbs to the more stable abdomen, we aim to enhance the accuracy and reliability of the device's measurements compared to traditional pulse oximeters. This design choice is particularly relevant for infants and young children, who often experience restlessness and movement during routine monitoring.

Successful accomplishment of this will result in a working prototype with motion artifact-resistant SpO2 reading error of less than 3.0% RMSE from SaO2. This development will allow the caregiver to continuously monitor accurate oxygen status Hypoxemic conditions, or medical problems stemming from low oxygen saturation, can result in half a million deaths annually. Oxygen saturation levels, which determine hypoxic conditions, can be measured directly from arterial blood. This is the gold standard of oxygen saturation measurement and is often called SaO2. Oxygen saturation measured from pulse oximetry, referred to as SpO2, uses light transmission and can allow for early detection of hypoxic conditions. It's a popular belief that melanin can absorb light in pulse oximetry, leading to the overestimation of SpO2 in darker skin. Although individuals with darker skin are observed to have a SpO2 overestimation, clinicians have yet to devise a method to accurately predict oxygen saturation given this overestimation[1]. Various clinical data has been curated to specifically address the issue of biases and disparities of pulse oximeter measurements in darker skin tones including the MIT Critical Datathon 2023 utilizing MIMIC IV and the blood-gas and oximetry linked dataset (BOLD)[2]. One issue with these datasets is race is often used as a proxy for skin tone, but there is great variability in skin color, even within a single race. Without an algorithm to account for how variation in skin tone biases in SpO2 measurement, a disproportionate amount of people of color may continue to receive incorrect diagnoses, leading to health inequities.

These incorrect diagnoses can lead to hidden hypoxemia, which is a condition where the gold standard oxygen saturation of a patient is less than 88% while the pulse oximeter measurement reads over 88%5. Studies show a significant disparity with black patients experiencing nearly three times the frequency of undetected hypoxemia compared to white patients6. They also emphasize the need to integrate pulse oximetry data with other clinical and patient-reported information to address this bias in medical technology.

These results are expected to generate evidence for proof-of-concept for this advanced next-generation pulse oximetry to be further tested and commercialized.

Tipo di studio

Osservativo

Iscrizione (Stimato)

100

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38105
        • Reclutamento
        • Le Bonheur Children's Hospital
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino

Accetta volontari sani

No

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Eligible infants hospitalized in the intensive care unit (PICU, PCVICU,NICU) who have already had an arterial line placed and on continuous pulse oximetry monitoring will be considered for enrollment and will be identified and approached for participation during their admission.

Descrizione

Inclusion Criteria:

  • 0-12 months of age. (Must be less than 1 year of life for the pulse oximeter portion of the study) Weight greater than 2 Kg at time of study
  • Admitted to an intensive care unit. (Not applicable for outpatient cohort)
  • Arterial line in place as standard of care (Not applicable for outpatient cohort)
  • Informed consent provided by parent or LAR.

Exclusion Criteria:

  • Open Sternum
  • Skin abnormalities at the proposed sensor site (e.g., rash, eczema, wounds, stoma, or infection)
  • Known allergy or sensitivity to adhesives or materials used in the sensor
  • Excessive movement or irritability that precludes safe and effective placement of the sensor
  • Parent or legal guardian unable to provide informed consent

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Abdominal SpO2 versus SaO2
Lasso di tempo: From enrollment to end of study at 72 hours.
The primary outcome is the accuracy of abdominal SpO₂ versus SaO₂, measured as root mean square error (RMSE); target ≤ 3.0% RMSE.
From enrollment to end of study at 72 hours.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 agosto 2026

Completamento primario (Stimato)

1 agosto 2028

Completamento dello studio (Stimato)

1 dicembre 2028

Date di iscrizione allo studio

Primo inviato

30 giugno 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 giugno 2026

Primo Inserito (Effettivo)

7 luglio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

7 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

30 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su vital sign monitoring

3
Sottoscrivi